Serial #97649707
DEAD

Serial Number

97649707

Owner

Eikon Therapeutics, Inc.

Attorney

Ilene B. Tannen

Filing Date

Oct 26, 2022

Add to watchlist:

No watchlists yet
View on USPTO

Serial #97649707 Trademark

Serial Number: 97649707

Serial #97649707 is a trademark filed by Eikon Therapeutics, Inc. on October 26, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Eikon Therapeutics, Inc. (10 trademarks)

3929 Point Eden Way
Hayward, CA 94545

Entity Type: 03

Trademark Details

Filing Date

October 26, 2022

Registration Date

Not Registered

Published for Opposition

January 2, 2024

Goods & Services

Pharmaceutical preparations comprising small molecules, biologics being biopharmaceuticals, and biologically active substances for the prevention and treatment of diseases and disorders, namely, cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterological disorders, dermatological disorders, endocrine disorders, infectious diseases, and ophthalmological disorders; vaccines; pharmaceutical preparations for the prevention and treatment of diseases and disorders, namely, cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterological disorders, dermatological disorders, endocrine disorders, infectious diseases, and ophthalmological disorders; biopharmaceuticals in the nature of pharmaceutical preparations for the prevention and treatment of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterological disorders, dermatological disorders, endocrine disorders, infectious diseases, and ophthalmological disorders; therapeutic pharmaceuticals for the prevention and treatment of diseases and disorders, namely, cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterological disorders, dermatological disorders, endocrine disorders, infectious diseases, and ophthalmological disorders; diagnostic substances, preparations, and agents for medical purposes

Pharmaceutical drug discovery and development services; Scientific and medical research, development and information services in the fields of pharmaceuticals, biopharmaceuticals, therapeutics, vaccines, diagnostics, and medicine discovery and development; Drug discovery and pharmaceutical development services for the pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine industries; Providing temporary use of on-line non-downloadable software for tracking and measuring movement of proteins in living cells for drug discovery and development; Providing temporary use of on-line non-downloadable software for tracking and measuring movement of proteins in living cells for pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine discovery and development services; Drug, pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine research and development and testing; Research and development of new products in the fields of drugs, pharmaceuticals, biopharmaceuticals, therapeutics, vaccines, diagnostics, and medicines; Biomedical research and development services in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Medical and clinical research and pharmaceutical development services to discover and develop medicines and vaccines in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Research, development, analysis, testing and consulting services in the fields of biochemistry, biotechnology, medicines, diagnostics, vaccines and pharmaceuticals; Scientific, medical, biological, biotechnology, biomedical, pharmaceutical research, development, analysis and testing services in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Scientific laboratory services, namely, live cell imaging analysis; Custom design and development of cells, cell lines and assays; Biomedical research services using a platform of biological tools and techniques for use in scientific research, drug and vaccine discovery and development; Providing a website featuring information in the fields of drug discovery and development, biochemistry, biotechnology, medicines, diagnostics, and pharmaceuticals; Provision of scientific, medical, biotechnology, biomedical, vaccine and pharmaceutical information regarding drug discovery, pharmaceutical products, vaccines and clinical trials; Providing a website featuring technology that allows users to conduct drug discovery and development; Providing a website featuring technology that allows users to track and measure movement of proteins in living cells

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 29, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 29, 2025 ABN6
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 25, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 25, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 25, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 25, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 25, 2025 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 30, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jan 30, 2025 EX2G
SOU EXTENSION 2 FILED
Jan 30, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 30, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 26, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jul 26, 2024 EX1G
SOU EXTENSION 1 FILED
Jul 26, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 26, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 27, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 2, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 2, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 13, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 27, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 27, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 27, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 27, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 27, 2023 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 29, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 29, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 29, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 9, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 10, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 9, 2022 NWOS
NEW APPLICATION ENTERED
Oct 29, 2022 NWAP